Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by GrahamBon Mar 05, 2021 2:21am
209 Views
Post# 32725528

RE:JAMA Cardiology Study

RE:JAMA Cardiology Study

Pandora wrote:

This study was done to do an analysis on athlete's hearts as to whether they were affected by covid.

https://jamanetwork.com/journals/jamacardiology/fullarticle/2777308

Method of Testing:  Troponin testing, electrocardiography (ECG), and resting echocardiography were performed after a positive COVID-19 test result. Interleague, deidentified cardiac data were pooled for collective analysis. Those with abnormal screening test results were referred for additional testing, including cardiac magnetic resonance imaging (MRI) and/or stress echocardiography.

Possibly replacing this method of testing or supplementing it with Ultrasound Plus VMS+3 would be a better approach.


 

 Thank you for putting this article on the Board.. I agree it’s very important, to  recognize the Cardiac complications of COVID is a growing public health problem, and that better imaging could facilitate diagnosis and management of these patients.

(Although, with vaccines now spreading rapidly throughout the world, hopefully COVID and this problem will be contained)

 

The suggestion you’ve raised, as have several others and even GA on the videos, is that the The VMS 3.0, could help in the management of COVID related cardiac disease.

 

The question is, why are cardiologists not adopting this technology then?

 

“Necessity is the mother of invention”, Has been a massive force in the advances we have seen in our society. COV ID, has transformed and accelerated adoption of new technologies, and the invention of new technology such as vaccines..

The firstMRNA Vaccines have been approved and already administered inside of the year in some countries, which is unheard of.

 

A really interesting report that deals with this rapid change and accelerated adoption  very recently put forth by MCKinsey, and the link is below here. The focus is on digital adoption, and they indicate that “the share of digital or digitally enabled products in their portfolios has accelerated by a shocking  seven years” .

This is also spreading to other technologies and services:  “Across regions, the results suggest a seven-year increase, on average, in the rate at which companies are developing these products and services” 

 

https://www.mckinsey.com/business-functions/strategy-and-corporate-finance/our-insights/how-covid-19-has-pushed-companies-over-the-technology-tipping-point-and-transformed-business-forever#

 

So, the point is, I agree completely with the concept, yet , Unless I have missed a video PR,it has not happened at all for VMS/VPT.

 

While many on this board are very educated about this technology, unless they are not announcing it, no one here is a cardiologist, and after all it is cardiologists who are going to have to agree with this concept and rapidly adopt this new technology.(or vets for pets...hey I am a poet and didn't even know it)

 

Yet adoption ofVPT  technologyit hasn’t happened in the past year, nor over the past decade.
'All this talk, but nada

 

I’m mentioning this, because my approach is to be rigorous, and question when I read statements, that would lead me to think about the promise, or the hype, which in turn make me think of profits and gets me greedy and excited.
 

 

Similarly, when people here Ihave been predicting 1-3 dollar Share price or a multibillion dollar company. What is the evidence for this? Relax...Hold on.. wait for it... It's coming... 

What is the model, the math, the revenue or profit projections that support this kind of lofty projections, andthinking?

 

Most posts, just make these random projections without any support for it, and a newbie can get excited thinking  the possibility and probability of this happening might be high.

Simply stated, it is more hype than beef, and a promotion they can lead the uninitiated to invest merely on a promise.

 

What is good about your post, Pandora is that you have produced a post, that provides some logical support for the thought. That’s actually great. 

 

The question is, is it realistic?

If so, why is there no articles in the cardiology literature, or multi centre clinical trials ongoing , or even just adoption of the technology since it’s approved, given the force of innovation and adoption of digital technologies and other technologies as noted widely and referenced above?

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse